A detailed history of Canandaigua National Corp transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Canandaigua National Corp holds 65,452 shares of BMY stock, worth $3.78 Million. This represents 0.8% of its overall portfolio holdings.

Number of Shares
65,452
Previous 66,262 1.22%
Holding current value
$3.78 Million
Previous $4.71 Million 0.04%
% of portfolio
0.8%
Previous 0.84%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 07, 2023

SELL
$68.48 - $81.09 $55,468 - $65,682
-810 Reduced 1.22%
65,452 $4.71 Million
Q3 2022

Oct 05, 2022

SELL
$0.13 - $76.84 $428 - $253,341
-3,297 Reduced 4.74%
66,262 $4.71 Million
Q2 2022

Jul 05, 2022

SELL
$72.62 - $79.98 $223,161 - $245,778
-3,073 Reduced 4.23%
69,559 $5.36 Million
Q1 2022

May 09, 2022

SELL
$61.48 - $73.72 $876,212 - $1.05 Million
-14,252 Reduced 16.4%
72,632 $5.3 Million
Q4 2021

Jan 04, 2022

SELL
$53.63 - $62.52 $27,673 - $32,260
-516 Reduced 0.59%
86,884 $5.42 Million
Q3 2021

Oct 04, 2021

BUY
$59.17 - $69.31 $276,442 - $323,816
4,672 Added 5.65%
87,400 $5.17 Million
Q2 2021

Jul 06, 2021

SELL
$61.91 - $67.42 $20,306 - $22,113
-328 Reduced 0.39%
82,728 $5.53 Million
Q1 2021

Apr 05, 2021

SELL
$59.34 - $66.74 $218,133 - $245,336
-3,676 Reduced 4.24%
83,056 $5.24 Million
Q4 2020

Feb 11, 2021

BUY
$57.74 - $65.43 $53,236 - $60,326
922 Added 1.07%
86,732 $5.38 Million
Q3 2020

Oct 19, 2020

BUY
$57.43 - $63.64 $148,111 - $164,127
2,579 Added 3.1%
85,810 $5.17 Million
Q2 2020

Jul 07, 2020

BUY
$54.82 - $64.09 $4.56 Million - $5.33 Million
83,231 New
83,231 $4.89 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Canandaigua National Corp Portfolio

Follow Canandaigua National Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Canandaigua National Corp, based on Form 13F filings with the SEC.

News

Stay updated on Canandaigua National Corp with notifications on news.